Antibacterial Drugs Market Expected to Reach USD 38.9 Billion Globally in 2023
According to a new market report published by Transparency Market Research “Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” the global antibacterial drugs market was valued at USD 43.9 billion in 2014 and is estimated to reach USD 38.8 billion by 2023 at a CAGR of (1.3%) from 2015 to 2023.
Antibacterial drugs have been utilized by humans since the discovery of the first antibiotic penicillin in 1928 by Alexander Fleming and has evolved into a multi-billion dollar market. These drugs treat infectious diseases caused by gram positive, gram negative, aerobic and anaerobic bacteria that cannot be treated by any other method unlike other diseases, where substitute methodologies are available. This property has made antibacterial drugs an indispensable part of human health care. Over the period, the bacteria have genetically mutated giving rise to multi-drug resistant (MDR) variants. The prevalence of MDR bacterial infections is also on a hike; according to World Health Organization (WHO) in 2013, there were about 480 000 new cases of multidrug-resistant tuberculosis (MDR-TB); extensively drug-resistant tuberculosis (XDR-TB) has been identified in 100 countries. MDR-TB requires treatment courses that are much longer and less effective than those for non-resistant TB.
Browse the Antibacterial Drugs Market Report at http://www.transparencymarketresearch.com/antibacterial-drugs-market.html
Antibacterial drugs are classified into eight major classes, namely, aminoglycosides, B-Lactams, tetracyclines, sulfonamides, quinolones, macrolides, phenicols and miscellaneous antibacterials. The B-lactams class was the largest segment of the global antibacterial drugs market in 2014, with 58% share. Quinolones was identified as the second largest class, which held a share of 17% of the global antibacterial drugs market in 2014 and is expected to report a negative CAGR during the forecast period. This decline in revenue will be primarily witnessed due to sales erosion from patent expiries, evolution of resistant strains of bacteria and rising concerns regarding tendon ruptures and tendon damage from fluoroquinolones administration. However, the demand for macrolides and quinolones/fluoroquinolones classes will remain high during the forecast period, due to their usage in treating a large number of infections coupled with expected launch of pipeline drugs in these classes during the forecast period.
The key drugs in pipeline have been identified for this market (currently in phase III clinical trials) and sales forecast has been provided for those expected to be launched during the forecast period (2015 to 2022). These include solithromycin (Cempra, Inc.), VivaGel (SPL7013) (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. These drugs promise to provide improved efficacy, shorter onset of action and fewer side effects as compared to the currently available antibacterial drugs. Hence, future commercialization of these drugs during the forecast period is anticipated to have a profound impact on the growth of the overall antibacterial drugs market.
AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players operating in the global antibacterial drugs market. These players have worldwide presence in the pharmaceutical industry and are involved in constant competition with each other. Pfizer, Inc. was observed to be the leading player in the antibacterial drugs market. Major end-users for antibacterial drugs include hospitals, private clinics, physicians and patients.
Browse the full Antibacterial Drugs Market (By Class- Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides, Phenicols and Miscellaneous
Browse the Press Release:http://www.transparencymarketresearch.com/pressrelease/antibacterial-drugs-market.htm
The global antibacterial drugs market has been segmented as below:
Global Antibacterial Drugs Market, by Drug Class, 2013 – 2023 (USD Million)
Aminoglycosides
B-Lactams
Tetracyclines
Sulfonamides
Quinolones/Fluoroquinolones
Macrolides
Phenicols
Miscellaneous Antibacterials
Pipeline Analysis of Antibacterial Drugs Market
Actoxumab/Aezlotoxumab, (MK-3415A)
Surotomycin (MK-4261)
Arikace
Cadazolid
Ciprofloxacin/Fluocinolone Acetonide
Zempia (E-101)
Carbavance (meropenem/RPX7009)
Ozenoxacin
RHB-105
SPL7013
Delafloxacin
Solithromycin (CEM-101)
Eravacycline
Delamanid
SYM-1219
Omadacycline (PTK-0796)
Plazomycin
Global Antibacterial Drugs Market, by Geography, 2013 – 2023 (USD Million)
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia-Pacific
China
Japan
Rest of Asia Pacific
Latin America
Brazil
Rest of Latin America
Rest of the World (RoW)
Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1567
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Antibacterial drugs have been utilized by humans since the discovery of the first antibiotic penicillin in 1928 by Alexander Fleming and has evolved into a multi-billion dollar market. These drugs treat infectious diseases caused by gram positive, gram negative, aerobic and anaerobic bacteria that cannot be treated by any other method unlike other diseases, where substitute methodologies are available. This property has made antibacterial drugs an indispensable part of human health care. Over the period, the bacteria have genetically mutated giving rise to multi-drug resistant (MDR) variants. The prevalence of MDR bacterial infections is also on a hike; according to World Health Organization (WHO) in 2013, there were about 480 000 new cases of multidrug-resistant tuberculosis (MDR-TB); extensively drug-resistant tuberculosis (XDR-TB) has been identified in 100 countries. MDR-TB requires treatment courses that are much longer and less effective than those for non-resistant TB.
Browse the Antibacterial Drugs Market Report at http://www.transparencymarketresearch.com/antibacterial-drugs-market.html
Antibacterial drugs are classified into eight major classes, namely, aminoglycosides, B-Lactams, tetracyclines, sulfonamides, quinolones, macrolides, phenicols and miscellaneous antibacterials. The B-lactams class was the largest segment of the global antibacterial drugs market in 2014, with 58% share. Quinolones was identified as the second largest class, which held a share of 17% of the global antibacterial drugs market in 2014 and is expected to report a negative CAGR during the forecast period. This decline in revenue will be primarily witnessed due to sales erosion from patent expiries, evolution of resistant strains of bacteria and rising concerns regarding tendon ruptures and tendon damage from fluoroquinolones administration. However, the demand for macrolides and quinolones/fluoroquinolones classes will remain high during the forecast period, due to their usage in treating a large number of infections coupled with expected launch of pipeline drugs in these classes during the forecast period.
The key drugs in pipeline have been identified for this market (currently in phase III clinical trials) and sales forecast has been provided for those expected to be launched during the forecast period (2015 to 2022). These include solithromycin (Cempra, Inc.), VivaGel (SPL7013) (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. These drugs promise to provide improved efficacy, shorter onset of action and fewer side effects as compared to the currently available antibacterial drugs. Hence, future commercialization of these drugs during the forecast period is anticipated to have a profound impact on the growth of the overall antibacterial drugs market.
AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players operating in the global antibacterial drugs market. These players have worldwide presence in the pharmaceutical industry and are involved in constant competition with each other. Pfizer, Inc. was observed to be the leading player in the antibacterial drugs market. Major end-users for antibacterial drugs include hospitals, private clinics, physicians and patients.
Browse the full Antibacterial Drugs Market (By Class- Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides, Phenicols and Miscellaneous
Browse the Press Release:http://www.transparencymarketresearch.com/pressrelease/antibacterial-drugs-market.htm
The global antibacterial drugs market has been segmented as below:
Global Antibacterial Drugs Market, by Drug Class, 2013 – 2023 (USD Million)
Aminoglycosides
B-Lactams
Tetracyclines
Sulfonamides
Quinolones/Fluoroquinolones
Macrolides
Phenicols
Miscellaneous Antibacterials
Pipeline Analysis of Antibacterial Drugs Market
Actoxumab/Aezlotoxumab, (MK-3415A)
Surotomycin (MK-4261)
Arikace
Cadazolid
Ciprofloxacin/Fluocinolone Acetonide
Zempia (E-101)
Carbavance (meropenem/RPX7009)
Ozenoxacin
RHB-105
SPL7013
Delafloxacin
Solithromycin (CEM-101)
Eravacycline
Delamanid
SYM-1219
Omadacycline (PTK-0796)
Plazomycin
Global Antibacterial Drugs Market, by Geography, 2013 – 2023 (USD Million)
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia-Pacific
China
Japan
Rest of Asia Pacific
Latin America
Brazil
Rest of Latin America
Rest of the World (RoW)
Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1567
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.